MCID: PRC012
MIFTS: 51

Pericardial Effusion

Categories: Cardiovascular diseases

Aliases & Classifications for Pericardial Effusion

MalaCards integrated aliases for Pericardial Effusion:

Name: Pericardial Effusion 12 54 6 15 71 32

Classifications:



External Ids:

Disease Ontology 12 DOID:118
MeSH 43 D010490
NCIt 49 C3319
SNOMED-CT 67 373945007
ICD10 32 I31.3
UMLS 71 C0031039

Summaries for Pericardial Effusion

Disease Ontology : 12 A pericardium disease that is characterized by an abnormal accumulation of fluid in the pericardial cavity.

MalaCards based summary : Pericardial Effusion is related to hemopericardium and pericardial tuberculosis. An important gene associated with Pericardial Effusion is ADA (Adenosine Deaminase), and among its related pathways/superpathways are p70S6K Signaling and Folate Metabolism. The drugs Diclofenac and Tadalafil have been mentioned in the context of this disorder. Affiliated tissues include heart, lung and breast, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 74 Pericardial effusion ("fluid around the heart") is an abnormal accumulation of fluid in the pericardial... more...

Related Diseases for Pericardial Effusion

Diseases in the Pericardial Effusion family:

Pericardial Effusion, Chronic

Diseases related to Pericardial Effusion via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 990)
# Related Disease Score Top Affiliating Genes
1 hemopericardium 34.4 TNNI3 PVR F2
2 pericardial tuberculosis 33.4 CRP ADA
3 cardiac tamponade 31.8 TNNI3 TNFRSF1A REN PVR PIK3C2A NPPB
4 myxedema 31.6 PIK3C2A NPPA MUC16
5 cardiogenic shock 31.3 PIK3C2A NPPB CRP
6 pericarditis 31.2 TNNI3 TNFRSF1A PIK3C2A NPPB IL6 CRP
7 brucellosis 31.2 IL6 CRP ADA
8 constrictive pericarditis 31.1 TNNI3 NPPB CRP ALB ADA ACE
9 hypothyroidism 31.1 VEGFA REN PIK3C2A F2 CRP ALB
10 myocarditis 31.1 TNNI3 PIK3C2A NPPB IL6 ACE
11 infective endocarditis 31.0 TNNI3 IL6 F2 CRP
12 atrial standstill 1 31.0 TNNI3 NPPB NPPA ACE ACADVL
13 pulmonary tuberculosis 31.0 IL6 CRP ALB ADA
14 uremia 30.9 REN IL6 CRP ALB ACE
15 connective tissue disease 30.9 VEGFA IL6 CRP ALB ACE
16 familial mediterranean fever 30.9 TNFRSF1A NLRP3 IL6 CRP
17 poems syndrome 30.9 VEGFA IL6 FGF2
18 hemangioma 30.9 VEGFA HIF1A FGF2 F2
19 acquired immunodeficiency syndrome 30.9 TNFRSF1A IL6 CRP ALB ADA
20 end stage renal disease 30.8 VEGFA REN IL6 CRP ALB ACE
21 rheumatic heart disease 30.8 NPPB IL6 ACE
22 mediastinitis 30.8 F2 CRP ALB
23 kawasaki disease 30.8 NPPB IL6 CRP ALB
24 chronic thromboembolic pulmonary hypertension 30.8 NPPB CRP
25 myeloma, multiple 30.8 VEGFA IL6 HIF1A FGF2 CRP ALB
26 juvenile rheumatoid arthritis 30.8 TNFRSF1A IL6 CRP ALB
27 acute kidney failure 30.8 REN PIK3C2A NPPA F2 ALB
28 endocarditis 30.7 TNNI3 PIK3C2A IL6 F2 CRP ALB
29 cardiac arrest 30.7 REN PIK3C2A NPPB ALB ACE
30 atrioventricular block 30.7 TNNI3 PIK3C2A NPPB ACE
31 heart aneurysm 30.7 IL6 CRP ALB
32 kaposi sarcoma 30.7 VEGFA IL6 HIF1A FGF2
33 pleural empyema 30.7 F2 CRP ALB ADA
34 inferior myocardial infarction 30.7 TNNI3 PIK3C2A NPPB
35 yellow nail syndrome 30.7 ALB ADA
36 kidney disease 30.7 REN NPPB NPPA IL6 CRP ALB
37 adult-onset still's disease 30.6 TNFRSF1A NLRP3 IL6 CRP
38 arthritis 30.6 VEGFA TNFRSF1A IL6 CRP ALB
39 meningitis 30.6 VEGFA NLRP3 IL6 CRP ALB ADA
40 coronary heart disease 1 30.6 NPPB IL6 CRP ACE
41 kwashiorkor 30.6 F2 CRP ALB
42 ovarian hyperstimulation syndrome 30.6 VEGFA REN IL6 ALB
43 systemic autoimmune disease 30.6 IL6 CRP
44 thrombophlebitis 30.6 F2 CRP ALB
45 bacterial meningitis 30.6 PIK3C2A IL6 CRP ALB
46 leishmaniasis 30.5 TNFRSF1A IL6 CRP ALB
47 sudden sensorineural hearing loss 30.5 IL6 F2
48 mitral valve stenosis 30.5 REN NPPB NPPA F2 CRP ACE
49 gastroenteritis 30.5 REN IL6 CRP ALB
50 amyloidosis 30.5 TNNI3 TNFRSF1A NPPB NLRP3 IL6 CRP

Graphical network of the top 20 diseases related to Pericardial Effusion:



Diseases related to Pericardial Effusion

Symptoms & Phenotypes for Pericardial Effusion

MGI Mouse Phenotypes related to Pericardial Effusion:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.35 ACADVL ACE ADA ALB CRP F2
2 homeostasis/metabolism MP:0005376 10.28 ACADVL ACE ADA ALB CRP F2
3 hematopoietic system MP:0005397 10.21 ACE ADA F2 FGF2 HIF1A IL6
4 immune system MP:0005387 10.15 ACE ADA ALB CRP F2 HIF1A
5 mortality/aging MP:0010768 10.1 ACADVL ACE ADA ALB F2 FGF2
6 digestive/alimentary MP:0005381 10.06 ADA ALB F2 HIF1A IL6 NLRP3
7 liver/biliary system MP:0005370 9.97 ACADVL ACE ADA ALB HIF1A IL6
8 muscle MP:0005369 9.9 ACADVL ADA ALB FGF2 HIF1A IL6
9 neoplasm MP:0002006 9.56 ACADVL ACE ALB FGF2 HIF1A IL6
10 renal/urinary system MP:0005367 9.36 ACE ADA ALB HIF1A IL6 NLRP3

Drugs & Therapeutics for Pericardial Effusion

Drugs for Pericardial Effusion (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 150)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
2
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
3
Ambrisentan Approved, Investigational Phase 4 177036-94-1 6918493
4
Silver sulfadiazine Approved, Vet_approved Phase 4 22199-08-2 441244
5
Treprostinil Approved, Investigational Phase 4 81846-19-7 6918140 54786
6
Colchicine Approved Phase 4 64-86-8 2833 6167
7
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
8
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
9
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
10
Ibuprofen Approved Phase 4 15687-27-1 3672
11
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
12
Dabigatran Investigational Phase 4 211914-51-1
13 Analgesics, Non-Narcotic Phase 4
14 Analgesics Phase 4
15 Cyclooxygenase Inhibitors Phase 4
16 Anti-Inflammatory Agents, Non-Steroidal Phase 4
17 Phosphodiesterase 5 Inhibitors Phase 4
18 Phosphodiesterase Inhibitors Phase 4
19 Antithrombins Phase 4
20 Antithrombin III Phase 4
21 Serine Proteinase Inhibitors Phase 4
22
protease inhibitors Phase 4
23 HIV Protease Inhibitors Phase 4
24 Anticoagulants Phase 4
25 Anti-Inflammatory Agents Phase 4
26 Hormones Phase 4
27 Antineoplastic Agents, Hormonal Phase 4
28 glucocorticoids Phase 4
29 Hormone Antagonists Phase 4
30 Antiemetics Phase 4
31 Gastrointestinal Agents Phase 4
32
Serine Investigational, Nutraceutical Phase 4 56-45-1 5951
33
Cetrorelix Approved, Investigational Phase 2, Phase 3 120287-85-6 16129715 25074887
34
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
35
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
36
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
37
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
38
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
39 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
40
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
41 Fibrinolytic Agents Phase 3
42 Tissue Plasminogen Activator Phase 3
43 Plasminogen Phase 3
44 Sclerosing Solutions Phase 3
45 Methylprednisolone Acetate Phase 3
46 Vaccines Phase 3
47 Tubulin Modulators Phase 3
48 Antirheumatic Agents Phase 3
49 Antimitotic Agents Phase 3
50
Bevacizumab Approved, Investigational Phase 2 216974-75-3

Interventional clinical trials:

(show top 50) (show all 100)
# Name Status NCT ID Phase Drugs
1 Atrial Fibrillation and Pericardial Drainage: Incidence of Postoperative Atrial Fibrillation According to the Type of Mediastinal Drainage Catheters Unknown status NCT02808897 Phase 4
2 Cochicine Treatment for Post- Operative Pericardial Effusion: The POPE 2 Study A Multicenter, Double-blind, Randomized Trial Completed NCT01266694 Phase 4 Colchicines;Placebo
3 the Post Operative Pericardial Effusion (POPE) Treatment Study Completed NCT00247052 Phase 4 diclofenac;diclofenac;matching placebo
4 A Controlled Randomized Trial of Circumferential Pulmonary Vein Ablation Versus Antiarrhythmic Drug Therapy in Treating Paroxysmal Atrial Fibrillation. The Ablation for Paroxysmal Atrial Fibrillation (APAF2) Trial Completed NCT00340314 Phase 4 Antiarrhythmic Drug Therapy
5 A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis Completed NCT01042158 Phase 4 tadalafil and ambrisentan upfront combination therapy
6 Impact of Colchicine Therapy on Arrhythmia Recurrence After Acute Pericardial Effusion Following Catheter Ablation of Atrial Fibrillation Recruiting NCT02260206 Phase 4 Colchicine
7 Comparison of Amplatzer Amulet vs Watchman Device in Patients Undergoing Left Atrial Appendage Closure: the SWISS-APERO Randomized Clinical Trial Recruiting NCT03399851 Phase 4
8 Effects of Treprostinil on Right Ventricular Structure and Function in Patients With Pulmonary Arterial Hypertension Recruiting NCT03835676 Phase 4 Treprostinil
9 Interventional Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in High-risk Patients With Atrial Fibrillation (PRAGUE-17 Study) Recruiting NCT02426944 Phase 4 NOAC
10 Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study). Active, not recruiting NCT03539055 Phase 4 Dabigatran Etexilate Oral Capsule
11 Dexamethasone Compared to Conventional Therapy in the Treatment of Acute Pericarditis: a Superiority Randomized Controlled Trial (Dexa-P) Not yet recruiting NCT04323280 Phase 4 Dexamethasone therapy;Conventional Therapy
12 A Trial of Complete Percutaneous Pericardial Drainage Facilitated by Intrapericardial Alteplase Compared to Conventional Pericardiocentesis When Indicated in Adults With Large Pericardial Effusion Due to Tuberculous and Non-tuberculous Pericarditis Unknown status NCT02673879 Phase 3
13 COlchicine for Prevention of the Post-pericardiotomy Syndrome and Post-operative Atrial Fibrillation (COPPS-2 Trial). Unknown status NCT01552187 Phase 3 Colchicine;Placebo
14 Sequential E2 Levels Not Ovarian Maximal Diameter Estimates Were Correlated With Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome Unknown status NCT02823080 Phase 2, Phase 3 Cetrorelix
15 A Randomized Controlled Trial to Evaluate the Efficacy of Intra-pericardial Instillation of a Sclerosing Agent After Pericardial Drainage in Patients With Malignant Pericardial Effusion Associated With Lung Cancer (JCOG9811) Completed NCT00132613 Phase 3 Pericardial instillation of bleomycin after drainage
16 A Trial of Adjunctive Prednisolone and Mycobacterium w Immunotherapy in Tuberculous Pericarditis Completed NCT00810849 Phase 3 Prednisolone
17 Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) Completed NCT00347412 Phase 3 Paclitaxel and Carboplatin;NOV-002 Injection in combination with Carboplatin vs. Paclitaxel and Carboplatin
18 Colchicine Versus Placebo in Post-Cardiac Surgery Patients to Prevent Post-Pericardiotomy Syndrome and Atrial Fibrillation Terminated NCT02177266 Phase 3 Colchicine;Placebo
19 Ablation of Paroxysmal Atrial Fibrillation Using the Appropriate Contact Force in a Chinese Population: A Prospective Randomized Single-center Trial Unknown status NCT02493075 Phase 1, Phase 2
20 Intrapleural Bevacizumab Injection for Treating Malignant Pleural or Pericardial Effusion in Non-small Cell Lung Cancer Completed NCT02054052 Phase 2 Bevacizumab
21 A Pilot Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer Completed NCT00318136 Phase 2 Bevacizumab;Carboplatin;Paclitaxel
22 Phase II Study of Cetuximab in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00251498 Phase 2 Cetuximab
23 Amgen Protocol 20060534 - A Phase 1b/2 Trial of AMG 479 or AMG 102 in Combination With Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer Completed NCT00791154 Phase 1, Phase 2 AMG 479;Etoposide;Placebo;AMG 102;Carboplatin;Cisplatin
24 A Phase I/II Study to Investigate the Safety, Tolerability and Potential Activity of IPI-504 in Relapsed and / or Refractory Stage IIIb (With Malignant Pleural or Pericardial Effusion), or Stage IV NSCLC Patients Completed NCT00431015 Phase 1, Phase 2 IPI-504
25 NGR014: Randomized Phase II Study of NGR-hTNF in Combination With Standard Chemotherapy Versus Standard Chemotherapy Alone in Previously Untreated Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Completed NCT00994097 Phase 2 NGR-hTNF;Cisplatin;Gemcitabine;Pemetrexed
26 Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in the Treatment of Postmenopausal Women With ER+Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Prior Letrozole or Anastrozole. Completed NCT01783444 Phase 2 Capecitabine;Exemestane;Everolimus
27 A Randomized Phase II Trial of Paclitaxel-Carboplatin or Gemicitabine-Cisplatin in ECOG Performance Status 2 Non-Small Cell Lung Cancer Patients Completed NCT00006004 Phase 2 carboplatin;cisplatin;gemcitabine hydrochloride;paclitaxel
28 Phase II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin as First Line Treatment in Patients With Stage IV Non-squamous Non Small Cell Lung Cancer (NSCLC) Completed NCT00942825 Phase 2 CBP501 + Cisplatin + Pemetrexed;Cisplatin + Pemetrexed
29 A Phase II Randomized Study of OSI-774 (Erlotinib) (NSC #718781) With or Without Carboplatin/Paclitaxel in Patients With Previously Untreated Adenocarcinoma of the Lung Who Never Smoked or Were Former Light Smokers Completed NCT00126581 Phase 2 Carboplatin;Erlotinib;Erlotinib Hydrochloride;Paclitaxel
30 Single Agent Alimta in Poor Performance Status in Patients With Non-Small Cell Lung Cancer (NSCLC) Completed NCT00508144 Phase 2 Alimta
31 A Phase II Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy Plus Dasatinib (NSC #732517) and Continuation Therapy With Dasatinib Alone in Newly Diagnosed Patients With Core Binding Factor Acute Myeloid Leukemia (AML) Active, not recruiting NCT01238211 Phase 2 Cytarabine;Dasatinib;Daunorubicin Hydrochloride
32 Randomized Phase II Trial of Individualized Adaptive Radiotherapy Using During-Treatment FDG-PET/CT and Modern Technology in Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting NCT01507428 Phase 2 18F-Fluoromisonidazole;Carboplatin;Fludeoxyglucose F-18;Paclitaxel
33 Hypofractionated Accelerated Radiotherapy With Concomitant Full Dose Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer: Phase I/II Study Active, not recruiting NCT02367443 Phase 1, Phase 2
34 Prevention of Postoperative Cardiac Arrythmias in Thoracic Surgery : Celiprolol Versus Diltiazem Not yet recruiting NCT03752931 Phase 2 Celiprolol;Diltiazem
35 Mesenchymal Stem Cell Administration in the Treatment of Coronary Graft Disease in Heart Transplant Patients Suspended NCT02472002 Phase 1, Phase 2
36 Compassionate Use of Catheter Thrombectomy (Aspirex 11F) in Patients With Massive Pulmonary Embolism Terminated NCT00314002 Phase 1, Phase 2
37 Phase II Trial of ILX295501 Administered Orally Once Weekly x 3 Repeated Every 6 Weeks in Patients With Stage III/IV Ovarian Cancer Withdrawn NCT00005645 Phase 2 ILX-295501
38 Phase I Clinical Trial of Autologous Mesothelin Re-directed T Cells in Patients With Chemotherapy Refractory Metastatic Pancreatic Cancer Completed NCT01897415 Phase 1
39 Collagenase Total Occlusion-1 Trial Completed NCT01271335 Phase 1
40 A Phase I Trial of Herceptin and Interleukin-12 Completed NCT00004074 Phase 1
41 A Phase I, Pharmacokinetic, and Biologic Correlative Study of R115777 (NSC 702818) and Herceptin in Patients With Advanced Cancer Completed NCT00005842 Phase 1 tipifarnib
42 Drainage or Pericardiocentesis Alone for Recurrent Non-malignant Pericardial Effusions Requiring Intervention. Unknown status NCT01665495
43 Clinical Audit of the Management of Pericarditis in Children. Unknown status NCT03253315
44 Functional and Morphological Cardiac Changes in Myeloproliferative Neoplasms Unknown status NCT03177928
45 Improvement of the Etiological Diagnosis of the Pericarditis Unknown status NCT02828085
46 Evaluation of the Cardiac Complications in Congenitally HIV-1 Infected Children in Israel by the Echocardiography and Measurement of N-Terminal Pro-B-Type Natriuretic Peptide (N-BNP). Unknown status NCT00426374
47 The Incidence of Significant Clinical Findings Using Focused Ultrasound Examination for the Heart, Lungs and Abdomen in Elderly Patients Before Emergent Surgery Unknown status NCT02824692
48 The Italian Society of Invasive Cardiology Registry on Percutaneous Aortic Valve Unknown status NCT02713932
49 Placement Of Cardiac PacemaKer Trial (POCKET)-RCT Unknown status NCT02931760
50 A Randomized Comparison of Excimer LASER vs Manual Thrombus Aspiration for the Prevention of No-reflow During Primary Percutaneous Coronary Intervention of St-elevation Myocardial Infarction(LASER-AMI Study) Unknown status NCT01826006

Search NIH Clinical Center for Pericardial Effusion

Genetic Tests for Pericardial Effusion

Anatomical Context for Pericardial Effusion

MalaCards organs/tissues related to Pericardial Effusion:

40
Heart, Lung, Breast, T Cells, Thyroid, Liver, Kidney

Publications for Pericardial Effusion

Articles related to Pericardial Effusion:

(show top 50) (show all 8391)
# Title Authors PMID Year
1
[Differentiation of malignant from nonmalignant, inflammatory pericardial effusions with biomarkers]. 61 54
20024642 2009
2
Adenosine deaminase in the diagnosis of tuberculous pericardial effusion. 61 54
18344697 2008
3
Adenosine deaminase and tuberculous pericarditis--a systematic review with meta-analysis. 54 61
16950165 2006
4
[Analysis of misdiagnosis in 33 cases of aortic dissection]. 61 54
16174592 2005
5
[A case of tuberculous pericarditis, the diagnosis of which was complicated by the delay in the rise of adenosine deaminase in the pericardial effusion]. 54 61
12806984 2003
6
The role of carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE) evaluation in pericardial fluid for the recognition of malignant pericarditis. 61 54
9479590 1997
7
Very long chain acyl-CoA dehydrogenase deficiency: successful treatment of acute cardiomyopathy. 61 54
8809347 1996
8
[The value of measuring adenosine deaminase activity in pericardial effusion fluid for diagnosing the etiology of pericardial effusion]. 61 54
9181887 1996
9
Adenosine deaminase and carcinoembryonic antigen in pericardial effusion diagnosis, especially in suspected tuberculous pericarditis. 61 54
8205688 1994
10
Usefulness of serum CA125 measurement for monitoring pericardial effusion. 54 61
8340995 1993
11
[Serum CA125 measurement is useful in 3 cases with pericardial effusion]. 54 61
8516579 1993
12
[Coronary arterial rupture during percutaneous transluminal coronary angioplasty: a case report]. 61 54
2104423 1990
13
Mid-Term Efficacy of Subxiphoid Versus Transpleural Pericardial Window for Pericardial Effusion. 61
32213328 2020
14
Prediction of adverse events in patients with initially medically treated type A intramural hematoma. 61
32223964 2020
15
[Hemoglobin drop after thrombolytic therapy in a 57-year-old stroke patient with "erosive gastritis"]. 61
32533196 2020
16
Thromboembolism and bleeding risk in atrial fibrillation ablation with uninterrupted anticoagulation between new oral anticoagulants and vitamin K antagonists: insights from an updated meta-analysis. 61
31686297 2020
17
Routine postoperative computed tomography is superior to cardiac ultrasonography for predicting delayed cardiac tamponade. 61
32221770 2020
18
A Pilot Study of Ultrasonography-Naïve Operators' Ability to Use Tele-Ultrasonography to Assess the Heart and Lung. 61
29806509 2020
19
Long-Term Outcome of Pericardial Drainage in Cases of Chronic, Large, Hemodynamically Insignificant, C-Reactive Protein Negative, Idiopathic Pericardial Effusions. 61
32345471 2020
20
Primary Mediastinal Large B-Cell Lymphoma in a Child Presenting With Superior Mediastinal Syndrome and Chylous Pleural and Pericardial Effusion. 61
30951026 2020
21
Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients. 61
32174129 2020
22
A Comprehensive Systemic Literature review of Pericardial Decompression Syndrome: Often Unrecognized and Potentially Fatal Syndrome. 61
32515313 2020
23
Pediatric ventricular assist device therapy for advanced heart failure-Hong Kong experience. 61
31624968 2020
24
A Case of Profound Hypothyroidism Presenting with Hypertensive Emergency and Large Amount of Pericardial Effusion. 61
32565535 2020
25
Preoperative Mild Pericardial Effusion Is Associated With Perioperative Complications In Elderly Patients Following Hip Fracture Surgery. 61
31475617 2020
26
Pericardial Effusion and Tamponade Complicating Acute Pericarditis in a Human Metapneumovirus-Infected Adult: A Unique Case Report. 61
32528782 2020
27
Myocardial edema in paroxysmal permeability disorders: The paradigm of Clarkson's disease. 61
32006896 2020
28
Echo-Guided Pericardiocentesis: When and How Should It Be Performed? 61
32572594 2020
29
Obstructive right ventricular outflow tract myxosarcoma in an adult dog. 61
32464578 2020
30
Transthoracic echocardiography monitoring during ASD closure using an artificial hand system. 61
32552906 2020
31
Diagnosis of a primary pericardial mesothelioma by the combination of conventional echocardiography and contrast echocardiography. 61
32542336 2020
32
Diagnostic Accuracy of Cardiac Computed Tomography and 18F-Fluorodeoxyglucose With Positron Emission Tomography in Cardiac Masses. 61
32563654 2020
33
Epicardial Interventions: Impact of Liposomal Bupivacaine on Postprocedural Management (The EPI-LIBRE Study). 61
32496820 2020
34
Subclavian and Axillary Vein Access Versus Cephalic Vein Cutdown for Cardiac Implantable Electronic Device Implantation: A Meta-Analysis. 61
32553216 2020
35
Intrapericardial instillation of bleomycin prevents recurrence of malignant pericardial effusions: Series of 46 cases and comprehensive literature review. 61
32513434 2020
36
Early Detection of Localized Immunity in Experimental Autoimmune Myocarditis Using [99mTc]Fucoidan SPECT. 61
31432389 2020
37
Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study. 61
31610707 2020
38
[Safety and efficiency of interventional electrophysiology utilizing the German "Belegarztsystem"]. 61
32372229 2020
39
Atypical cardiac defects in patients with RASopathies: Updated data on CARNET study. 61
32558384 2020
40
Cardiogenic shock as the initial manifestation of systemic lupus erythematosus. 61
32515553 2020
41
Isolated Exercise-Induced Pulmonary Hypertension Associates with Higher Cardiovascular Risk in Scleroderma Patients. 61
32570917 2020
42
Massive pericardial effusion causing cardiac tamponade accompanied by elevated CA-125 and thoracic lymphadenopathy in sarcoidosis: a case report. 61
32563820 2020
43
Not just another large atrial septal defect: complex anatomy, challenging procedure, and an unusual complication. 61
32539899 2020
44
[Cardiac Tamponade as Cardio-Oncologic Emergency Disease]. 61
32541160 2020
45
Active chest tube clearance after aortic valve surgery did not influence amount residual pericardial fluid after aortic valve replacement in a randomised trial. 61
32122153 2020
46
Sandwich repair for postinfarction ventricular septal rupture and left ventricular rupture. 61
32529504 2020
47
The Clinical and Chest CT Features Associated With Severe and Critical COVID-19 Pneumonia. 61
32118615 2020
48
COVID-19 and Congenital Heart Disease: Results from a Nationwide Survey. 61
32521643 2020
49
Novel coronavirus disease 2019: predicting prognosis by using a computed tomography severity score and clinicolaboratory data. 61
32500700 2020
50
Pleural and Pericardial Effusion as the Only Manifestation of IgG4-Related Disease. 61
32499098 2020

Variations for Pericardial Effusion

ClinVar genetic disease variations for Pericardial Effusion:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 NLRP3 NM_001079821.2(NLRP3):c.1805A>G (p.Gln602Arg)SNV Likely pathogenic 374002 rs1057518827 1:247588550-247588550 1:247425248-247425248
2 SERPINA11 NM_001080451.2(SERPINA11):c.672C>A (p.Tyr224Ter)SNV Likely pathogenic 631492 14:94912913-94912913 14:94446576-94446576

Expression for Pericardial Effusion

Search GEO for disease gene expression data for Pericardial Effusion.

Pathways for Pericardial Effusion

Pathways related to Pericardial Effusion according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.88 REN IL6 HIF1A FGF2 F2 ACE
2
Show member pathways
12.17 IL6 F2 CRP ALB
3 12.08 TNFRSF1A NLRP3 IL6 F2
4
Show member pathways
11.94 TNFRSF1A NPPB NPPA FGF2
5 11.61 VEGFA IL6 HIF1A FGF2
6
Show member pathways
11.58 VEGFA HIF1A ADA
7 11.56 REN NPPA ACE
8
Show member pathways
11.49 VEGFA TNFRSF1A IL6
9 11.49 VEGFA NPPA IL6 HIF1A
10 11.36 VEGFA IL6 HIF1A
11 11.31 VEGFA IL6 FGF2
12 11.24 VEGFA PIK3C2A FGF2
13 11.19 F2 ALB ACADVL
14 11.15 VEGFA TNNI3 IL6 FGF2 ALB
15
Show member pathways
10.97 VEGFA HIF1A CRP
16 10.52 VEGFA HIF1A
17 10.51 VEGFA HIF1A FGF2

GO Terms for Pericardial Effusion

Cellular components related to Pericardial Effusion according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.83 VEGFA TNFRSF1A SERPINA11 REN PVR NPPB
2 extracellular space GO:0005615 9.5 VEGFA TNFRSF1A SERPINA11 REN PVR NPPB

Biological processes related to Pericardial Effusion according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.84 NPPA IL6 F2 ALB
2 response to hypoxia GO:0001666 9.71 VEGFA NPPA HIF1A ADA
3 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.7 VEGFA TNFRSF1A IL6
4 positive regulation of endothelial cell proliferation GO:0001938 9.69 VEGFA HIF1A FGF2
5 cGMP biosynthetic process GO:0006182 9.57 NPPB NPPA
6 negative regulation of lipid storage GO:0010888 9.56 IL6 CRP
7 receptor guanylyl cyclase signaling pathway GO:0007168 9.55 NPPB NPPA
8 positive regulation of blood vessel endothelial cell migration GO:0043536 9.54 VEGFA HIF1A FGF2
9 neutrophil mediated immunity GO:0002446 9.49 IL6 ACE
10 positive regulation of T-helper 2 cell cytokine production GO:2000553 9.48 NLRP3 IL6
11 negative regulation of thymocyte apoptotic process GO:0070244 9.46 HIF1A ADA
12 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.43 VEGFA HIF1A
13 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.43 VEGFA PIK3C2A FGF2
14 cytokine-mediated signaling pathway GO:0019221 9.35 VEGFA TNFRSF1A IL6 HIF1A FGF2
15 acute-phase response GO:0006953 9.33 IL6 F2 CRP
16 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.32 VEGFA ACE
17 regulation of blood pressure GO:0008217 8.92 REN NPPB NPPA ACE

Molecular functions related to Pericardial Effusion according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone receptor binding GO:0051427 8.96 NPPB NPPA
2 growth factor activity GO:0008083 8.92 VEGFA IL6 FGF2 F2

Sources for Pericardial Effusion

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....